Key Insights

Highlights

Success Rate

84% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.1%

3 terminated out of 33 trials

Success Rate

84.2%

-2.3% vs benchmark

Late-Stage Pipeline

9%

3 trials in Phase 3/4

Results Transparency

25%

4 of 16 completed with results

Key Signals

4 with results84% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (9)
P 1 (1)
P 2 (4)
P 3 (2)
P 4 (1)

Trial Status

Completed16
Recruiting5
Active Not Recruiting4
Unknown4
Terminated3
Withdrawn1

Trial Success Rate

84.2%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT05524077Not ApplicableActive Not Recruiting

Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia

NCT06546137RecruitingPrimary

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

NCT07077005Not ApplicableRecruitingPrimary

Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy

NCT06253221Phase 3Active Not RecruitingPrimary

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05582395Phase 3CompletedPrimary

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

NCT06034405Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

NCT06112743Phase 4Active Not RecruitingPrimary

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT07127640Not ApplicableActive Not RecruitingPrimary

Effect of an Aerobic Exercise Session on Cardiovascular and Autonomic Parameters of Adults With Hypertrophic Cardiomyopathy

NCT05556343Phase 2TerminatedPrimary

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT04580693CompletedPrimary

The Impact of Exercise-Induced Cardiac Remodeling on Myocardial Efficiency

NCT04164732Phase 2CompletedPrimary

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

NCT03057002CompletedPrimary

UTSW HP [13-C] Pyruvate Injection in HCM

NCT05646056Completed

A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk

NCT05610215Not ApplicableRecruiting

Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy

NCT03450252Not ApplicableCompletedPrimary

Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy

NCT04905173Not ApplicableWithdrawn

Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy

NCT04222101Not ApplicableTerminated

Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy

NCT03225001Not ApplicableCompleted

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve

NCT03040947UnknownPrimary

MRI Sequence and Imaging Protocol Development

NCT02417311UnknownPrimary

Individualized Early Risk Assessment for Heart Diseases

Scroll to load more

Research Network

Activity Timeline